Loading...
Please wait, while we are loading the content...
Similar Documents
Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden.
| Content Provider | Semantic Scholar |
|---|---|
| Author | Davidson, Thomas Husberg, Magnus Janzon, Magnus Oldgren, Jonas Levin, Lars-Åke |
| Copyright Year | 2013 |
| Abstract | AIMS Patients with atrial fibrillation have a significantly increased risk of thromboembolic events such as ischaemic stroke, and patients are therefore recommended to be treated with anticoagulation treatment. The most commonly used anticoagulant consists of vitamin K antagonist such as warfarin. A new oral anticoagulation treatment, dabigatran, has recently been approved for stroke prevention among patients with atrial fibrillation. The purpose of this study was to estimate the cost-effectiveness of dabigatran as preventive treatment of stroke and thromboembolic events compared with warfarin in 65-year-old patients with atrial fibrillation in Sweden. METHODS AND RESULTS A decision analytic simulation model was used to estimate the long-term (20-year) costs and effects of the different treatments. The outcome measures are the number of strokes prevented, life years gained, and quality-adjusted life years (QALYs) gained. Costs and effect data are adjusted to a Swedish setting. Patients below 80 years of age are assumed to start with dabigatran 150 mg twice a day and switch to 110 mg twice a day at the age of 80 years due to higher bleeding risk. The price of dabigatran in Sweden is €2.82 (Swedish kronor 25.39) per day for both doses. The cost per QALY gained for dabigatran compared with warfarin is estimated at €7742, increasing to €12 449 if dabigatran is compared with only well-controlled warfarin treatment. CONCLUSION Dabigatran is a cost-effective treatment in Sweden, as its incremental cost-effectiveness ratio is below the normally accepted willingness to pay limit. |
| Starting Page | 1991 |
| Ending Page | 1999 |
| Page Count | 9 |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/34/3/10.1093/eurheartj/ehs157/2/ehs157.pdf?Expires=1491278225&Key-Pair-Id=APKAIUCZBIA4LVPAVW3Q&Signature=XlXetakbh~bfaC3gEftsLonwlYcaAVZamH-x38wyK24wrJ7KJzjbieCGTWBhurXmHWKa2xJMU2WSPsaep5J~f~9ciWsel2l5uqY~zC7mlKZbtF7A8IW4qNN~jq-e5G8mA6Jw646npmAkYIbqEunO3JueMPpkVOlciNZ7lMl8l6alLh1yCQyBpkXYmpk~PR2aBpUmwl1ADPuEO8o0q-yYPhNOvnxuTlqS5e9Bd56dlHeBnCuH-~uglgbTRiJbHl7snA0lxaIT9gLeldTD8LO8H0PfRM3U1QrDMcrTY86YbjSKU5j4z33J27Uv2T0X2KCxIruti3aQgOp4-xvpczp5bA__ |
| Alternate Webpage(s) | https://watermark.silverchair.com/ehs157.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAjkwggI1BgkqhkiG9w0BBwagggImMIICIgIBADCCAhsGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMYS_5-cPE7lvttuVfAgEQgIIB7CylvMpX8qbVGMsv2Uf5O5f4xDCzbEitFKd8pay3sAATE43gMbYWenPgt_luGNgWSby0vMcYjXeSA9KG1hjVq2SqAf9VR-dIdLaYD8KtebbyCqwj2ScQepJVVviqglDqgi1N2ijXUg8fnGElvM7djS9VgtQnj4puCKIJtnRa1JG9CikVwxQpwTIFqcMR9YCm2G7CiKuxXQoW7RDoGhpCzIRIz_Oe405kGZ6gUS82kgOv7q9sJ9_Ol7YkaAQsc7-EnRMzS-MogFkLwC9jQZo6mEtyDcwK0uTbYs_4NmA-QdnnUCCOzmiiAy7zwBYJofscl5WNNUqFMdaXf1c0Yr1Xb9MmtiWsgZx_vYy1nsa0hIbzr_zVith31XtmRRh8O6TFhB2mnh4obhRSLAzahAKuurcXJtEOE4sKOy1Vg-4uoaObY0mD2ZTk_KOtWhncLU9kJCNuzkvrGufb_0CFfWWK4FsMyNqfba9JlS2AQtM8wk5if22c9eYtv9kpIExOMA9p9U7BkyrucF2AZZt19Or3xTPtnKN_7oErc5lIrzKTExDVzdLndkr1PShwN1c8h8-yzAtEq15ayHua38WzO2KrA6ehU7hxVbLVzahraaIN0oOVywN6FrW1X_15neBhvxv5EJAUPKthHOKtp7S3-g |
| PubMed reference number | 22733833v1 |
| Alternate Webpage(s) | https://doi.org/10.1093/eurheartj/ehs157 |
| DOI | 10.1093/eurheartj/ehs157 |
| Journal | European heart journal |
| Volume Number | 34 |
| Issue Number | 3 |
| Language | English |
| Access Restriction | Open |
| Subject Keyword | Anticoagulants Anticoagulation Therapy Atrial Fibrillation Cerebral Infarction Cerebrovascular accident Cost Effectiveness Eighty Gain Heart Atrium Hemorrhage Increment Patients Thromboembolism Vitamin K Warfarin dabigatran |
| Content Type | Text |
| Resource Type | Article |
